Implantation of XEN‑45 for Treatment of Refractory Secondary Glaucoma
By
Kun Lv
Zhiqiao Liang
Kuankuan Wu
Yao Ma
Kangyi Yang
Wenbo Liu
Huijuan Wu
November 14, 2025
Clinical Scorecard: Implantation of XEN‑45 for Treatment of Refractory Secondary Glaucoma
At a Glance
Category Detail
Condition Refractory Secondary Glaucoma Key Mechanisms Elevated intraocular pressure (IOP) due to identifiable factors leading to glaucomatous optic neuropathy. Target Population Patients with uncontrolled IOP exceeding 21 mmHg or requiring multiple anti-glaucoma medications. Care Setting University-based glaucoma clinic.
Key Highlights
XEN-45 Gel Stent offers a minimally invasive alternative to traditional glaucoma surgeries. Effective for various forms of refractory secondary glaucoma including uveitic and steroid-induced glaucoma. Implantation techniques include ab interno and ab externo methods, with ab externo gaining popularity. Guideline-Based Recommendations
Diagnosis
Diagnosis of secondary glaucoma requires evidence of disease progression and elevated IOP. Management
Initial treatment involves medical therapy; surgical options are for cases uncontrolled by medications. Monitoring & Follow-up
Regular follow-up for IOP measurement and assessment of visual field defects is essential. Risks
Traditional surgeries pose risks of complications such as hypotony and bleb leaks. Patient & Prescribing Data
Patients with refractory secondary glaucoma, including those with uveitis, trauma, and steroid-induced conditions.
XEN-45 gel stents have shown effectiveness in managing IOP with fewer complications compared to traditional methods.
Clinical Best Practices
Utilize minimally invasive techniques to reduce surgical trauma and recovery time. Ensure thorough pre-operative assessment of conjunctival health and prior surgical history. Related Resources & Content
